CSIMarket
 


Anixa Biosciences Inc   (ANIX)
Other Ticker:  
 

Anixa Biosciences Inc 's Working Capital Ratio

ANIX's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth




ANIX Working Capital Ratio (Oct 31 2022)
IV. Quarter
(Jul 31 2022)
III. Quarter
(Apr 30 2022)
II. Quarter
(Jan 31 2022)
I. Quarter
(Oct 31 2021)
IV. Quarter
Y / Y Current Liabilities Change 60.33 % 22.68 % -16.09 % 20.36 % 12.1 %
Y / Y Current Assets Change -16.12 % -12.72 % -15.36 % 140.27 % 284.3 %
Working Capital Ratio MRQ 14.83 22.01 27.39 19.58 28.34
Overall Ranking # 370 # 303 # 0 # 235 # 282
Seq. Current Liabilities Change 38.67 % 23.55 % -33.46 % 40.65 % 6.1 %
Seq. Current Assets Change -6.62 % -0.68 % -6.95 % -2.8 % -2.83 %



Working Capital Ratio forth quarter 2022 Comment
Due to increase in Current Liabilities in the forth quarter 2022, Working Capital Ratio fell to 14.83 below Anixa Biosciences Inc average.

Within Major Pharmaceutical Preparations industry 84 other companies have achieved higher Working Capital Ratio than Anixa Biosciences Inc in forth quarter 2022. While Working Capital Ratio total ranking has deteriorated compare to the prior quarter from 303 to 370.

Explain Working Capital Ratio
Where is ANIX most successful ?
Working Capital Ratio ANIX on the trailing twelve month basis
Working Capital Ratio forth quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 85
Healthcare Sector # 132
Overall Market # 370


Working Capital Ratio Statistics
High Average Low
30.94 8.03 0.29
(Jul 31 2021)   (Jan 31 2014)




Financial Statements
Anixa Biosciences Inc 's Current Liabilities $ 2 Millions Visit ANIX's Balance sheet
Anixa Biosciences Inc 's Current Assets $ 30 Millions Visit ANIX's Balance sheet
Source of ANIX's Sales Visit ANIX's Sales by Geography


Cumulative Anixa Biosciences Inc 's Working Capital Ratio

ANIX's Working Capital Ratio for the trailling 12 Months

ANIX Working Capital Ratio

(Oct 31 2022)
IV. Quarter
(Jul 31 2022)
III. Quarter
(Apr 30 2022)
II. Quarter
(Jan 31 2022)
I. Quarter
(Oct 31 2021)
IV. Quarter
Y / Y Current Liabilities TTM Growth 60.33 % 22.68 % -16.09 % 20.36 % 12.1 %
Y / Y Current Assets TTM Growth -16.12 % -12.72 % -15.36 % 140.27 % 284.3 %
Working Capital Ratio TTM 20.07 23.78 25.83 25.83 23.48
Total Ranking TTM # 139 # 167 # 157 # 236 # 150
Seq. Current Liabilities TTM Growth 38.67 % 23.55 % -33.46 % 40.65 % 6.1 %
Seq. Current Assets TTM Growth -6.62 % -0.68 % -6.95 % -2.8 % -2.83 %


TTM Working Capital Ratio Comment
On the trailing twelve months basis Due to growth in Current Liabilities in the IV. Quarter to $2.04 millions, average cumulative Working Capital Ratio decreased to 20.07 below the Anixa Biosciences Inc average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 50 other companies have achieved higher Working Capital Ratio than Anixa Biosciences Inc . While Working Capital Ratio overall ranking has improved so far to 0, from total ranking in previous quarter at 157.

Explain Working Capital Ratio
Where is ANIX most successful ?
Working Capital Ratio ANIX on the trailing twelve month basis

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 51
Healthcare Sector # 76
Within the Market # 139


TTM Working Capital Ratio Statistics
High Average Low
24.96 10.4 0.33
(Apr 30 2022)   (Dec. 30, 2013)




Companies with similar Working Capital Ratio in the quarter ending Oct 31 2022, within Major Pharmaceutical Preparations Industry Working Capital RatioOct 31 2022 MRQ Current AssetsOct 31 2022 MRQ Current Liabilities
Synaptogenix Inc   39.98 $ 27.329  Millions$ 0.684  Millions
Design Therapeutics Inc   33.47 $ 348.488  Millions$ 10.412  Millions
Kezar Life Sciences Inc   31.15 $ 298.927  Millions$ 9.595  Millions
Merrimack Pharmaceuticals Inc  30.42 $ 13.628  Millions$ 0.448  Millions
Karuna Therapeutics Inc   29.93 $ 1,219.678  Millions$ 40.745  Millions
Nextcure Inc   29.76 $ 175.315  Millions$ 5.891  Millions
Anebulo Pharmaceuticals Inc  28.38 $ 19.815  Millions$ 0.698  Millions
Theseus Pharmaceuticals inc   27.54 $ 214.997  Millions$ 7.806  Millions
Spruce Biosciences Inc   27.43 $ 93.186  Millions$ 3.397  Millions
Cyteir Therapeutics Inc   27.05 $ 157.348  Millions$ 5.816  Millions
Immix Biopharma Inc   26.90 $ 17.391  Millions$ 0.647  Millions
Savara Inc   26.55 $ 137.069  Millions$ 5.163  Millions
Imago Biosciences Inc   25.95 $ 182.040  Millions$ 7.015  Millions
Ironwood Pharmaceuticals inc   25.78 $ 698.994  Millions$ 27.117  Millions
Terns Pharmaceuticals Inc   25.47 $ 190.537  Millions$ 7.481  Millions
Oramed Pharmaceuticals Inc   25.44 $ 160.172  Millions$ 6.297  Millions
Nanoviricides inc   25.37 $ 13.153  Millions$ 0.518  Millions
Eqrx Inc   25.33 $ 1,523.990  Millions$ 60.163  Millions
Infinity Pharmaceuticals Inc   25.28 $ 49.350  Millions$ 1.952  Millions
Morphic Holding inc   25.09 $ 382.410  Millions$ 15.241  Millions
Io Biotech Inc   24.96 $ 157.751  Millions$ 6.321  Millions
Diamedica Therapeutics Inc   24.31 $ 36.490  Millions$ 1.501  Millions
Pasithea Therapeutics Corp   24.21 $ 44.469  Millions$ 1.837  Millions
Seres Therapeutics Inc   23.69 $ 247.513  Millions$ 10.449  Millions
Anaptysbio inc  23.15 $ 450.444  Millions$ 19.459  Millions
Dice Therapeutics Inc   22.96 $ 267.837  Millions$ 11.665  Millions
Pmv Pharmaceuticals Inc   22.75 $ 265.176  Millions$ 11.656  Millions
Eliem Therapeutics Inc   22.46 $ 133.171  Millions$ 5.928  Millions
Keros Therapeutics Inc   22.21 $ 245.875  Millions$ 11.070  Millions
Cassava Sciences Inc   22.06 $ 183.272  Millions$ 8.308  Millions

Date modified: 2023-01-05T10:18:53+00:00

Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

MOBQ's Profile

Stock Price

MOBQ's Financials

Business Description

Fundamentals

Charts & Quotes

MOBQ's News

Suppliers

MOBQ's Competitors

Customers & Markets

Economic Indicators

MOBQ's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071